Figure 2.

Clinical trial outcome measures that may be considered for inclusion as components of composite endpoints in PH‐ILD trials. Large Δ infers larger changes, while smaller Δ infers lesser changes. Clinical progression composites are heralded by lesser change, while clinical worsening infers greater change or more meaningful events. The NT‐proBNP can be used either with a progression or worsening categorical change event to provide biomarker validation. 6MWD six‐minute walk distance; HrQOL, health‐related quality of life; NT‐proBNP, N‐terminal prohormone of brain natriuretic peptide; QoL, quality of life.